Table 9.
Biological activity of lipid SLNs and NLCs formulates against epimastigotes of Trypanosoma cruzi (CL strain, clone B5)
| Formulate | Epimastigotes | |
|---|---|---|
| 256 μΜ ± SD (N = 9)* | IC50 (N = 9)† | |
| SLN 5 | 40.7 ± 7.7 | 48.8 ± 14.3 |
| SLN 10 | 28.5 ± 12.7 | 70.0 ± 17. |
| SLN 20 | 39.0 ± 2.3 | 123.9 ± 19.7 |
| NLC 5 | 12.5 ± 2.1 | 93.9 ± 12.2 |
| NLC 10 | 39.4 ± 2.8 | 119.8 ± 13.4 |
| NLC 20 | 49.9 ± 3.1 | 256.0 ± 19.9 |
| NLC 5′ | 31.6 ± 6.5 | 47.4 ± 17.7 |
| NLC 10’ | 23.4 ± 0.9 | 41.3 ± 9.9 |
| NLC 20’ | 24.2 ± 1.2 | 44.3 ± 7.5 |
| NLC 30’ | 51.6 ± 1.2 | Not feasible |
| NLC 20 ‘' | 31.5 ± 1.1 | 53.9 ± 2.0 |
| BNZ | 15.8 ± 4.9 | 17.7 ± 2.1 |
BNZ = benznidazole; NLC = nanostructured lipid carriers; SD = standard deviation; SLN = solid lipid nanoparticles.
*
The results are the mean value of epimastigote growth (%) at the highest concentration tested (256 μΜ) ± SD (N = 9).
†
The concentration causing 50% cellular growth inhibition was calculated using GraphPad Prism software.